Phospholipid (Cardiolipin) Antibodies, IgG, Serum
Use
This test is useful for identifying the presence of antiphospholipid antibodies, particularly anticardiolipin antibodies, which are relevant in diagnosing antiphospholipid syndrome (APS). Patients with APS may experience unexplained arterial or venous thrombosis, pregnancy morbidity such as unexplained fetal death, premature birth, or recurrent miscarriages, and may have systemic autoimmune diseases like systemic lupus erythematosus or unexplained skin manifestations. This test aids in the clinical evaluation when combined with other antiphospholipid antibody tests.
Special Instructions
Not provided.
Limitations
Immunoassays for detecting anticardiolipin antibodies may not fully distinguish between autoantibodies specific to APS and those produced in response to infections. There is interlaboratory variability in assay results due to differences in commercial immunoassays. Persistent antibody detection is required for a definitive APS diagnosis, and repeated testing is necessary to confirm persistent presence.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Cardiolipin IgG
Protein
LOINC Codes
- 3181-5 - Cardiolipin IgG Ser IA-aCnc
- 3181-5 - Cardiolipin IgG Ser IA-aCnc
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Serum gel or red top tube, aliquot into plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial
Causes for Rejection
Gross hemolysis, gross lipemia, heat-treated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |